文献速递妇科

子宫动脉栓塞治疗子宫肌瘤的不良事件报告分析

Analysis of Reported Adverse Events with Uterine Artery Embolization for Leiomyomas.
PubMed 文献 · J Minim Invasive Gynecol · 2018-08-29

本研究回顾性分析了制造商与用户设施设备体验(MAUDE)数据库中1998年至2018年与子宫动脉栓塞治疗子宫肌瘤相关的不良事件报告。共纳入193份报告,疼痛最常见(68例,35.2%),其次为阴道分泌物(45例,23.3%)、操作失误(37例,19.2%)和发热或感染并发症(36例,18.7%);27例(14.0%)需手术干预,其中子宫切除术占7.8%,死亡5例(2.6%)。作者鼓励医生在使用医疗器械时查阅MAUDE数据库。

要点

  • 疼痛是子宫动脉栓塞治疗肌瘤最常报告的不良事件(68例,35.2%)。
  • 27例(14.0%)需手术干预,子宫切除术报告率为7.8%。
  • 死亡事件报告5例(2.6%)。

核心结论

  • MAUDE数据库可能有助于临床医生识别FDA批准医疗器械的不良事件和并发症。
  • 作者鼓励医生在使用医疗器械时查阅MAUDE数据库,因为它是评估器械相关不常见但重大问题的重要工具。

研究设计与样本

  • 回顾性审查MAUDE数据库,检索1998年至2018年与子宫动脉栓塞相关的事件报告(加拿大任务组分类III)。

主要发现

  • 共识别193份报告。
  • 疼痛最常见(68例,35.2%),其次为阴道分泌物(45例,23.3%)、操作失误(37例,19.2%)、发热或感染并发症(36例,18.7%)。
  • 27例(14.0%)需手术干预,子宫切除术报告率为7.8%。
  • 死亡5例(2.6%)。

临床怎么用

  • 作者鼓励医生在使用医疗器械时查阅MAUDE数据库。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

STUDY OBJECTIVE: To analyze and investigate reports associated with uterine artery embolization used for treatment of myomas using this database. DESIGN: A retrospective review of the Manufacturer and User Facility Device Experience (MAUDE) database for events related to uterine artery embolization (Canadian Task Force Classification III). SETTING: The MAUDE database was accessed online. PATIENTS: Patients with myomas undergoing uterine artery embolization. INTERVENTIONS: The MAUDE database was accessed online and searched for events related to uterine artery embolization reported between 1998 and 2018. These reports were reviewed and analyzed, reported events were categorized, and other relevant information was collected and tabulated. MEASUREMENTS AND MAIN RESULTS: A total of 193 reports published during the study period were identified. Pain was the most frequently reported event (68 events; 35.2%), followed by vaginal discharge (45 events; 23.3%), operational misfire (37 events; 19.2%), and fever or infectious complications (36 events; 18.7%). A surgical procedure was required in 27 events (14.0%), with hysterectomy reported in 7.8% of the events. Death following this procedure was mentioned in 5 events (2.6%). CONCLUSION: The MAUDE database may be useful for clinicians using a Food and Drug Administration-approved medical device to identify the occurrence of adverse events and complications. A variety of adverse events associated with the use of uterine artery embolization were reported to the MAUDE database related to its use in the treatment of uterine myomas. We encourage physicians to review the MAUDE database when using medical devices, because this is an important tool to assess uncommon but major problems that could be associated with a medical device.

来源:J Minim Invasive Gynecol,查看原文。版权归原作者所有。

引用

  1. Armstrong AA, Kroener L, Brower M, et al. Analysis of Reported Adverse Events with Uterine Artery Embolization for Leiomyomas. J Minim Invasive Gynecol. 2018. PMID: 30016750. doi:10.1016/j.jmig.2018.07.006

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。